{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(17)"],"submitter":["Pura L"],"pubmed_abstract":["<h4>Background</h4>Chronic kidney disease (CKD) is largely driven by inflammation. Mesenchymal stem cells (MSCs) show therapeutic potential; however, their efficacy across CKD etiologies remains unclear.<h4>Methods</h4>Comprehensive searches were conducted in PubMed, Cochrane, ScienceDirect, Scopus and Google Scholar. Effect sizes for inflammation and renal function outcomes were meta-analyzed.<h4>Results</h4>Of 2514 studies screened, 52 met inclusion criteria (49 animal studies, 3 randomized controlled trials). In animal models, MSCs significantly reduced interleukin-6 (mean difference [MD] = -155.80; 95% CI: -249.10, -62.51; <i>p</i> = 0.001) and tumor necrosis factor-α (TNF-α) (MD = -35.53; 95% CI: -52.75, -18.30; <i>p</i> < 0.0001). In patients, TNF-α reduction was not significant (MD "],"journal":["Cells"],"pagination":["1313"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12428256"],"repository":["biostudies-literature"],"pubmed_title":["Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis."],"pmcid":["PMC12428256"],"pubmed_authors":["Putri RD","Prahmana MA","Bandiara R","Pura L","Faried A","Wijaya MP","Supriyadi R"],"additional_accession":[]},"is_claimable":false,"name":"Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.","description":"<h4>Background</h4>Chronic kidney disease (CKD) is largely driven by inflammation. Mesenchymal stem cells (MSCs) show therapeutic potential; however, their efficacy across CKD etiologies remains unclear.<h4>Methods</h4>Comprehensive searches were conducted in PubMed, Cochrane, ScienceDirect, Scopus and Google Scholar. Effect sizes for inflammation and renal function outcomes were meta-analyzed.<h4>Results</h4>Of 2514 studies screened, 52 met inclusion criteria (49 animal studies, 3 randomized controlled trials). In animal models, MSCs significantly reduced interleukin-6 (mean difference [MD] = -155.80; 95% CI: -249.10, -62.51; <i>p</i> = 0.001) and tumor necrosis factor-α (TNF-α) (MD = -35.53; 95% CI: -52.75, -18.30; <i>p</i> < 0.0001). In patients, TNF-α reduction was not significant (MD ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-04-08T19:11:02.627Z","creation":"2026-04-08T12:05:49.395Z"},"accession":"S-EPMC12428256","cross_references":{"pubmed":["40940724"],"doi":["10.3390/cells14171313"]}}